Login
Home / NCNA : NASDAQ
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

NuCana plc

$1.32 -$2.32 (-63.74%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$1.32
Day Range
$1.31$1.37
Year Range
$1.21$7.22
Market Cap
8.02M
AVG Volume
58.47K
Trailing/Forward PE
-0.33/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
2026-11-12
Primary Exchange
NASDAQUS
Revenue (GBP)
00.250.50.75124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Net Income (GBP)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Operating Income (GBP)
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EBITDA (GBP)
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash Flows (GBP)
-10M-7.5M-5M-2.5M02.5M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EPS (GBP)
-150-100-50024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Expenses (GBP)
05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash & Debt (GBP)
010M20M30MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Debt ratios
00.511.524 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Margins
0%50%100%150%17 Q4
Return on Capital
-400%-300%-200%-100%0%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Shares Outstanding
02M4M6M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Book Value Per Share (GBP)
05010015024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Total Assets (GBP)
010M20M30M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Employee Count
010203040201720182019202020212022202320242025
Free Cash Flow Yield
-20000%-15000%-10000%-5000%0%med -141.66%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Book
0100200300400med 0.36Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NuCana plc
NCNA
Stockpicker

Video analysis: NCNA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: NCNA

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

globenewswire.com · 13 Aug 2026

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial results for the second quarter ended June 30, 2026 and provided an update on its clinical development program with its two lead anti-cancer medicines. “NuCana continues to build momentum as we advance NUC-7738 closer to several important clinical and regulatory milestones,” said Hugh S.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.